Citi placed an “upside 90-day catalyst watch” on shares of Arcturus Therapeutics (ARCT) ahead of the Phase 2 cystic fibrosis readout expected in Q4. The firm sees a favorable risk/reward for the shares into the data and keeps a Buy rating on Cystic Fibrosis with a $49 price target
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ARCT:
- Arcturus Therapeutics Partners on New COVID-19 Vaccine Launch
- Cathie Wood Scales Back Roku and Roblox Stakes, Boosts Arcturus Holding
- Cathie Wood Continues Selling Tempus AI and Roku Shares
- Cathie Wood’s ARK Investment buys 28.3K shares of Arcturus Therapeutics today
- Cathie Wood Pours $49M into Brera Holdings, Trims Roku and Tempus AI Stakes